ライフサイエンスコーパス: intellectual property

1 regarding consent for future data mining and intellectual property.

2 to reduce environmental release and protect intellectual property.

3 emia; particularly when addressing issues of intellectual property.

4 , and acquire novel chemical space to secure intellectual property.

5 readiness to benefit financially from their intellectual property.

6 or to resolve disputes over the ownership of intellectual property.

7 nd may place limitations on the licensing of intellectual property.

8 or to make or sell products that embody the intellectual property.

9 patient privacy, regulatory compliance, and intellectual property.

10 ng fidelity, and ensuring responsible use of intellectual property.

11 s obtained from an international database on intellectual property.

12 s of engineered organisms, and protection of intellectual properties.

13 ng patents that dominate embryonic stem cell intellectual property?

14 east one such dispute in the previous year), intellectual property (30 percent), and control of or ac

15 protection, technical infrastructure setup, intellectual property agreement, and efficient communica

16 estions, including increasing concerns about intellectual property and conflict of interest.

17 ive explains how to work through the general intellectual property and contractual issues for all res

18 nancial data, due to regulatory limitations, intellectual property and privacy control, still hinder

19 l report of a problem through discussions of intellectual property and sample management, study desig

20 f medical research, the process of patenting intellectual property, and its potential impact on facul

21 outlined: define policy solutions to patent, intellectual property, and liability law barriers; creat

22 ervices, honoraria, expenses, royalty/patent/intellectual property, and other disclosures.

23 a wealth of new knowledge, become topics of intellectual property, and spawned a vibrant field of ca

24 bs, whose geographical indication or similar intellectual properties are economically important, henc

25 d court decisions if they are to seek useful intellectual property as a basis for technology transfer

26 e issues of regulatory approval, patents and intellectual property, assessment of value and cost-effe

27 aws constrain the use of property, including intellectual property, by a firm with market power and m

28 Notably, intellectual property can be protected prior to publicat

29 derused, partially because of regulatory and intellectual property challenges.

30 s, publication and protection from premature intellectual property claims.

31 ngly challenging for both the scientific and intellectual-property communities.

32 ow to involve regulatory, manufacturability, intellectual property, competitive assessments, business

33 each polymer takes years to optimize, secure intellectual property, comply with the regulatory bodies

34 o the vagaries and potential divisiveness of intellectual property considerations.

35 ine has decisively liberated states from the intellectual property constraints that bind private corp

36 In the intellectual property context, an obligation to make pro

37 ion is vital, for example in cases involving intellectual property disputes and in monitoring and saf

38 eric competition and aid drug companies with intellectual property extensions, tax relief and guarant

39 Academic ownership of intellectual property facilitated wide dissemination and

40 ment measures (ie, subsequent grant funding, intellectual property, faculty appointment/promotion, or

41 els made up of persons who have expertise in intellectual property, finance, and research, but who ar

42 stry since decades and constitutes important intellectual property for the individual company, betwee

43 on the discoveries made by faculty to create intellectual property, form new companies and seek inves

44 pidly and openly, creating a rich, open, and intellectual property-free knowledge base for future ant

45 onfluence of the Web and a spirit of sharing intellectual property have fueled a worldwide movement t

46 Inventors seeking to protect their intellectual property in Europe now have an important ch

47 r academic institutions to track outcomes of intellectual property in the therapeutics domain.

48 d the opportunities and pitfalls of patents, intellectual property, investors and biotechnology start

49 t ESM for novel applications, leading to new intellectual property (IP) and patenting opportunities.

50 rchers need to be aware of patents and other intellectual property (IP) considerations to ensure that

51 ic stability, cardiac safety, and beneficial intellectual property (IP) issues.

52 also ascertain that they have a very strong intellectual property (IP) position to weather competiti

53 ransfer, and compulsory licensing of vaccine intellectual property (IP).

54 e, challenges related to legal, ethical, and intellectual property issues persist.

55 ity, promoting appropriate use, and managing intellectual property issues.

56 Using an example from intellectual property law, we demonstrate that it is pos

57 The intellectual property laws in the United States provide

58 ers and acquisitions, patents granted to MIT intellectual property licensees, drug candidates discove

59 nts were more likely to receive funding from intellectual property licensing (27% vs 16%, P = .01).

60 It is clear that the intellectual property model challenged by the Myriad dec

61 erMaterials, and patent links from the World Intellectual Properties Organization (WIPO).

62 Generic repurposed agents lack intellectual property protection and are rarely advanced

63 ue growth, especially in sectors with strong intellectual property protection and technologies with h

64 Strengthened intellectual property protection manifested by the rise

65 ows scientists consider the proliferation of intellectual property protection to have a strongly nega

66 Besides cost, other factors such as intellectual property protection, problem solving skills

67 Implications of strengthened intellectual property provisions for equitable access to

68 ing data publicly available sometimes raises intellectual property questions in the minds of depositi

69 essential for addressing part obsolescence, intellectual property recovery, compliance, quality assu

70 Intellectual property regimes, technology regulatory fra

71 individuals and institutions that developed intellectual property related to stent technology early

72 research organization and productivity, and intellectual property remain to be examined.

73 ly valuable PET radiopharmaceuticals without intellectual property residing in regulatory limbo, with

74 e publicly available, and not subject to any intellectual property restrictions.

75 There is a need to assess intellectual property rights ("IPRs") that may impede ge

76 Advances in protection of intellectual property rights (IPR) are also applicable t

77 Within the past century, however, intellectual property rights (IPRs) have threatened this

78 res to optimally manage data, materials, and intellectual property rights (IPRs).

79 tion's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) set global minimum

80 Protection of intellectual property rights encourages private sector i

81 The intellectual property rights for some genes can become h

82 scheme based on the market availability and intellectual property rights forFDA approved drugs.

83 Because all intellectual property rights have been provided free of

84 However, the recent proliferation of intellectual property rights in biomedical research sugg

85 Controversy over intellectual property rights in the results of large-sca

86 chnology research cites ethical, safety, and intellectual property rights issues.

87 Otherwise, more intellectual property rights may lead paradoxically to f

88 such as support for research and education, intellectual property rights protection, low barriers to

89 t are important to them, namely, production, intellectual property rights, and product liability, mus

90 confidential, protected by regulations about intellectual property rights.

91 f patients, and attitudes to the eschewal of intellectual property rights.

92 erty, substantially increasing and expanding intellectual-property rights, and generated clear gains

93 rea, the proximity of processing facilities, intellectual property, safety and economics.

94 iological Diversity and the Nagoya Protocol; intellectual property; sample accessioning; and biosecur

95 nient way for researchers to claim their own intellectual property since the designer's information c

96 ience, providing entry to novel chemical and intellectual property space.

97 obal minimum standards for the protection of intellectual property, substantially increasing and expa

98 Patents are intellectual properties that reflect innovative activiti

99 An analysis of recent trends in intellectual property that impact early- to mid-stage li

100 addressed the distribution of royalties from intellectual property, the future use of archival sample

101 f publication, authorship, data-sharing, and intellectual property vary considerably.

102 also serve as a good strategy for developing intellectual properties which will be critical for produ

103 lerating enzyme discovery and development of intellectual property will also be highlighted.

104 s in the United States provide the owners of intellectual property with discretion to license the rig